UNH Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

113.38B

+12.47%

2.110

-69.02%

113.75B

+3.81%

6.612

-8.17%

113.47B

+1.66%

4.424

+8.43%

Estimates Revision

The market is revising Downward the revenue expectations for UnitedHealth Group Incorporated (UNH) for FY2025, with the revenue forecasts being adjusted by -0.11% over the past three months. During the same period, the stock price has changed by 0.39%.

Revenue Estimates for FY2025

Revise Downward

-0.11%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.42%

In Past 3 Month

Stock Price

Go Up

+0.39%

In Past 3 Month

21 Analyst Rating

Wall Street analysts forecast UNH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UNH is 393.95 USD with a low forecast of 260.00 USD and a high forecast of 440.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

17 Buy

3 Hold

1 Sell

Strong Buy

Current: 341.100

Low

260.00

Averages

393.95

High

440.00

Current: 341.100

Low

260.00

Averages

393.95

High

440.00

TD Cowen

Hold

maintain

$335 -> $338

2025-10-30

Reason

TD Cowen

Price Target

$335 -> $338

2025-10-30

maintain

Hold

Reason

TD Cowen raised the firm's price target on UnitedHealth to $338 from $335 and keeps a Hold rating on the shares. The firm updated its model as Q3 results checked a lot of boxes; adjusted EPS beat, FY25 guide raise, tax rate/investment income inline. They raise the target but keep the P/E target unchanged.

Bernstein

Lance Wilkes

Outperform

maintain

$433 -> $440

2025-10-30

Reason

Bernstein

Lance Wilkes

Price Target

$433 -> $440

2025-10-30

maintain

Outperform

Reason

Bernstein analyst Lance Wilkes raised the firm's price target on UnitedHealth to $440 from $433 and keeps an Outperform rating on the shares. The firm has updated its UnitedHealth EPS model post-Q3 earnings. Bernstein expects a sector-wide turnaround as MA and Medicaid recover from trough margins following MA rate shocks, withdrawal of competition, and redeterminations. The firm sees evidence that pricing discipline is being restored in MA and Optum Health, which will shock growth in the short-term but restore margin more swiftly. Bernstein sees UnitedHealth's valuation as attractive given its expectation for outsized EPS growth recovery over the next 4 years.

BofA

Neutral

maintain

$390 -> $410

2025-10-29

Reason

BofA

Price Target

$390 -> $410

2025-10-29

maintain

Neutral

Reason

BofA raised the firm's price target on UnitedHealth to $410 from $390 and keeps a Neutral rating on the shares. Q3 was "a little surprising" in that UHC margins outperformed while Optum Health and Insight both came in below expectations, the analyst tells investors. The "good news" is that UnitedHealth was able to handle the incremental investment and raised guidance by 25c, giving the firm more confidence that "it gave itself plenty of cushion" in its Q2 guidance reset, adds the analyst, who also raised the firm's estimates to reflect updated guidance.

Oppenheimer

Outperform

maintain

$325 -> $415

2025-10-29

Reason

Oppenheimer

Price Target

$325 -> $415

2025-10-29

maintain

Outperform

Reason

Oppenheimer raised the firm's price target on UnitedHealth to $415 from $325 and keeps an Outperform rating on the shares. The firm notes the company produced solid Q3 results, raising its outlook and reiterating most long-term targets. For MA, the outlook remains on track with prior comments, with 2026 margins expected to improve in 2026 and then return to the top-end of its 2%-4% target range by 2027. Meanwhile, OptumHealth expects margin improvement in 2026 as it rebounds toward long-term target margins of 6%-8%, Oppenheimer adds. Overall, the firm believes these results were a first positive step for UnitedHealth, which is setting more realistic goals as it looks to re-establish credibility with the Street.

RBC Capital

Ben Hendrix

Outperform

maintain

$286 -> $408

2025-10-29

Reason

RBC Capital

Ben Hendrix

Price Target

$286 -> $408

2025-10-29

maintain

Outperform

Reason

RBC Capital analyst Ben Hendrix raised the firm's price target on UnitedHealth to $408 from $286 and keeps an Outperform rating on the shares after its Q3 earnings beat. The management voiced confidence in pricing actions and plan exits driving margin expansion across the enterprise next year, the analyst tells investors in a research note. With expectations of margin improvement accelerating in 2027, UnitedHealth should see EPS growth near the low-end of its long-term annual EPS growth target of 13%-16%, the firm added.

UBS

Buy

maintain

$378 -> $430

2025-10-29

Reason

UBS

Price Target

$378 -> $430

2025-10-29

maintain

Buy

Reason

UBS raised the firm's price target on UnitedHealth to $430 from $378 and keeps a Buy rating on the shares. UnitedHealth sounded more confident on the growth trajectory for 2027 and beyond, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for UnitedHealth Group Inc (UNH.N) is 20.18, compared to its 5-year average forward P/E of 20.58. For a more detailed relative valuation and DCF analysis to assess UnitedHealth Group Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

20.58

Current PE

20.18

Overvalued PE

23.83

Undervalued PE

17.34

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

14.44

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

16.34

Undervalued EV/EBITDA

12.55

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1.19

Current PS

0.00

Overvalued PS

1.43

Undervalued PS

0.94

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

UNH News & Events

Events Timeline

No data

News

8.5

09:00 AMNASDAQ.COM

Zacks Industry Forecast for UnitedHealth, Humana, and Centene

6.5

08:04 AMYahoo Finance

Top Warren Buffett Stocks to Invest in with $1,000 Today

6.5

12-15NASDAQ.COM

Three HMO Stocks to Watch Amid Increasing Medical Expenses and Regulatory Challenges

People Also Watch

Frequently Asked Questions

What is UnitedHealth Group Inc (UNH) stock price today?

The current price of UNH is 341.1 USD — it has decreased -0.22 % in the last trading day.

What is UnitedHealth Group Inc (UNH)'s business?

UnitedHealth Group Incorporated is a healthcare and well-being company. Its segments include Optum Health, Optum Insight, Optum Rx, and UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State. Optum Health offers comprehensive and patient-centered care, addressing the physical, mental, social, and financial well-being. Optum Health delivers primary, specialty and surgical care; helps patients and providers navigate and address complex, chronic and behavioral health needs. Optum Insight connects the healthcare system with services, analytics and platforms that make clinical, administrative and financial processes simpler and more efficient for all participants in the healthcare system. Optum Rx offers a range of pharmacy care services through retail pharmacies, through home delivery, specialty and community health pharmacies and the provision of in-home and community-based infusion services.

What is the price predicton of UNH Stock?

What is UnitedHealth Group Inc (UNH)'s revenue for the last quarter?

UnitedHealth Group Inc revenue for the last quarter amounts to 113.16B USD, increased 12.24 % YoY.

What is UnitedHealth Group Inc (UNH)'s earnings per share (EPS) for the last quarter?

UnitedHealth Group Inc. EPS for the last quarter amounts to 2.59 USD, decreased -60.22 % YoY.

What changes have occurred in the market's expectations for UnitedHealth Group Inc (UNH)'s fundamentals?

How many employees does UnitedHealth Group Inc (UNH). have?

UnitedHealth Group Inc (UNH) has 400000 emplpoyees as of December 16 2025.

What is UnitedHealth Group Inc (UNH) market cap?

Today UNH has the market capitalization of 309.65B USD.